Paul L. Berns - Feb 18, 2025 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Title: Chief Executive Officer and Chairman of the Board, Director
Signature
/s/ Michael Milligan, as Attorney-in-Fact for Paul L. Berns
Stock symbol
NMRA
Transactions as of
Feb 18, 2025
Transactions value $
-$23,468
Form type
4
Date filed
2/20/2025, 05:14 PM
Previous filing
Feb 18, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NMRA Common Stock Sale -$23.5K -13.9K -0.19% $1.69 7.41M Feb 18, 2025 Direct F1, F2
holding NMRA Common Stock 133K Feb 18, 2025 See footnote F3
holding NMRA Common Stock 133K Feb 18, 2025 See footnote F4
holding NMRA Common Stock 133K Feb 18, 2025 See footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 19, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.
F2 This transaction was executed in multiple trades in prices ranging from $1.66 to $1.745, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Held by LULU TRUST OF 2024 FBO AB.
F4 Held by LULU TRUST OF 2024 FBO OB.
F5 Held by LULU TRUST OF 2024 FBO HB.

Remarks:

Title: Chief Executive Officer and Chairman of the Board